Distribution has been halted for generic Ranitidine after an announcement that the US Food and Drug Administration (FDA) is investigating medications containing ranitidine that may have a possible link to cancer.

This generic medication is taken by millions to help with gastrointestinal disorders and discomfort. The manufacturer stated that this is a “precautionary distribution stop” as they complete an internal investigation and the FDA continues its own research to determine if the low levels of the ingredient pose a risk to patients.

If you or a family member has been prescribed this generic medication, here are some key points to know about this issue:

• Brand-name Zantac is not included in the distribution halt. Those currently on the generic version can purchase the brand-name over-the-counter medication.
• Pediatric patients on liquid ranitidine do not need to switch. The halt only involves the capsule/tablet version.
• This is currently a distribution halt, not a recall. The manufacturer is taking precautionary measures as investigations continue and more information will be released as it becomes available.